Skip to content
Menu

PRF Technologies Ltd. PRFX

Full chart Compare
Set alert

Price alert · PRFX

All alert types
0.62 USD -0.02 (-3.78%)

Regular-session close

0.62 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

0.6076 Day range 0.6399
0.604 52-week range 7.95
YTD
-80.58%
1 year
-85.90%

5D -0.0660 (-9.24%)

0.60000.70000.8000ThuFriMonTueWed0.6479
Market cap
2.18M
EPS (ttm)
-4.09
Shares out
874.86K
Forward P/E
-0.37
YTD return
-80.58%
1-year return
-85.90%
50-day average
1.84
Volume
28.61K
Avg volume
228.89K
Open
0.6313
Previous close
0.6479
Day's range
0.6076 – 0.6399
52-week range
0.604 – 7.95
Beta
0.56

Key statistics

200-day average
3.57
Enterprise value
339.62K
Free cash flow
-4.93M
Total cash
2.78M
Total debt
59.00K
Return on equity
-716.67%
Short % of float
9.08%

Fundamental scorecard

5 of 25 checks passed on PRFX’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
PRFX Revenue — quarterly 0
PRFX Net income — quarterly -7.31M
PRFX EPS — quarterly 10.00

Earnings

PRFX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 15, 2024Jun 1, 20240.00-9.60——
May 15, 2024Mar 1, 20240.00-65.27——
Feb 29, 2024Dec 1, 20230.00———
Nov 15, 2023Sep 1, 20230.0011.52——
May 15, 2023Mar 1, 20230.00-52.79——
Mar 16, 2023Dec 1, 20220.00-69.59——

Upgrades / downgrades

PRFX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 24, 2024Maxim GroupdownBuyHold
Jun 26, 2024Maxim GroupreitBuyBuy

About PRF Technologies Ltd.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Israel

News

Your note

Sign in to keep a note on PRFX — it syncs with the Stock Master app.

Institution ownership

PRFX institution ownership
Holder% heldSharesValueReported
UBS Group AG0.74%6,49628.97KSep 29, 2024
Two Sigma Securities, LLC0.49%4,30819.21KSep 29, 2024
HRT Financial LP0.41%3,57715.95KSep 29, 2024
Osaic Holdings Inc0.02%192856Sep 29, 2024

Fund ownership

PRFX fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.01%80356Sep 29, 2024